Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

China · Delayed Price · Currency is CNY

16.41

+0.11 (0.67%)

Jul 31, 2026, 3:04 PM CST

62.15% (1Y)

Market Cap	8.84B +62.2%
Revenue (ttm)	1.31B +22.2%
Net Income	3.93M
EPS	0.01
Shares Out	538.65M
PE Ratio	2,248.50
Forward PE	12.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,723,745
Open	17.89
Previous Close	16.30
Day's Range	16.35 - 17.89
52-Week Range	9.40 - 24.18
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancro... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 1,663

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300497

Full Company Profile

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -55.03 million, -79.78% less than in 2024.

Financial Statements